Drawing for DIMENSION THERAPEUTICS

USPTO serial 87449309

DIMENSION THERAPEUTICS

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
KHAN, AHSEN M
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with DIMENSION THERAPEUTICS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Jessica S. Parise

JESSICA S. PARISE GOODWIN PROCTER LLP620 EIGHTH AVENUETHE NEW YORK TIMES BUILDINGNEW YORK, NY 10018

Goods and services

ClassDescriptionStatusFirst use
001Chemical and biochemical products for use in gene delivery technology, namely, nucleic acids, coding and non-coding deoxyribonucleic acids, ribonucleic acids, plasmids, vectors, promotors, enhancers and other regulatory sequences, all for in-vivo laboratory use in gene therapyACTIVE—
005Pharmaceutical preparations for the treatment of genetic diseases and disorders; Pharmaceutical preparations for the treatment of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, and fungal and viral diseases and disorders; pharmaceutical preparations for the treatment of cancer, pain, diabetes, damaged skin, damaged tissue and addiction; Gene therapy and prophylaxis products, namely, gene transfer, regulation, modulation and delivery pharmaceutical preparations for the treatment of genetic diseases and disordersACTIVE—
042Biomedical and scientific research in the fields of genome editing, gene editing, genome engineering, gene modulation, genetic diseases, gene therapy, and cell therapy; product development in the fields of genetic therapies and effectors to regulate, modulate, and characterize disease states; pharmaceutical research and development in the field of gene therapy; conducting clinical trials for others in the field of gene therapy design and delivery; biomedical research in the field of gene therapy design and delivery; diagnostics services in the field of equipment used for gene therapy design and delivery; gene therapy design and delivery development of biochemical assaysACTIVE—
044Providing medical services, namely, gene therapy medical services in the field of genetic diseases and disorders; providing medical services, namely, gene therapy medical services in the field of liver, hepatological, cardiovascular, central nervous system, endocrine, gastrointestinal, immunological, dermatological, infectious, inflammatory, menopausal, metabolic, autoimmune, musculoskeletal, neurological, ophthalmologic, psychiatric, respiratory, urogenital, urological, hematologic, fungal and viral diseases and disorders; dispensing of pharmaceutical preparations for the treatment of cancer, pain, diabetes, damaged skin, damaged tissue and addictionACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Dec 10, 2018MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Dec 10, 2018ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
May 8, 2018NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
Mar 13, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 13, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 21, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 7, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Feb 7, 2018XAECEXAMINER'S AMENDMENT ENTERED—
Feb 7, 2018GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Feb 7, 2018GNEAEXAMINERS AMENDMENT E-MAILED—
Feb 7, 2018CNEAEXAMINERS AMENDMENT -WRITTEN—
Aug 14, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 14, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 14, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Aug 14, 2017DOCKASSIGNED TO EXAMINER—
May 18, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
May 18, 2017NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance